Pulmonary Fibrosis News

April 13, 2016April 13, 2016

Pulmonary Fibrosis Foundation Enrolls 1st Person in PFF Patient Registry, a Research Tool

The Pulmonary Fibrosis Foundation (PFF) announced it has enrolled its first pulmonary fibrosis (PF) patient in the newly launched PFF Patient Registry, a collaborative effort involving patients, researchers, and healthcare providers that will gather data to advance ... Read more

December 21, 2015

Systemic Sclerosis and Lung Fibrosis Study of Nintedanib Enrolls First Patient

Pulmonary Fibrosis News, Scleroderma

Boehringer Ingelheim recently announced the enrollment of the first patient in its global, double-blind, randomized, and placebo-controlled SENSCIS (Safety and Efficacy of Nintedanib in Systemic SClerosIS) Phase 3 clinical trial. The trial (NCT02597933) is now ... Read more

November 11, 2015November 11, 2015

Pulmonary Fibrosis Research, Patient Care Gets a Boost

News, Pulmonary Fibrosis News

Boehringer Ingelheim Pharmaceuticals, Inc. and the Pulmonary Fibrosis Foundation (PFF) have announced a five-year partnership in an effort to raise awareness for the disease and provide patients with disease ... Read more

August 26, 2015October 26, 2015

Vagus Nerve Found To Regulate Pulmonary Fibrosis Progression

News, Pulmonary Fibrosis News

In a new study entitled “Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice,” researchers investigated the role of the vagus nerve in pulmonary fibrosis pathogenesis. They established a mouse model and ... Read more

August 13, 2015August 13, 2015

ESTAIR Clinical Trial Enrolling for Treatment of Idiopathic Pulmonary Fibrosis

News, Pulmonary Fibrosis News

An international group of researchers are currently recruiting participants for Sanofi’s Phase 2 trial of SAR156597 for the treatment of idiopathic pulmonary fibrosis (IPF). The official title of the trial, ... Read more

August 12, 2015December 16, 2015

Genentech’s ESBRIET Recommended in ATS Guidelines for IPF Treatment

News, Pulmonary Fibrosis News

Genentech recently announced in a statement that Esbriet (pirfenidone) has been recommended in the new American Thoracic Society’s (ATS) idiopathic pulmonary fibrosis (IPF) treatment guidelines. This recommendation, which is published as ... Read more

August 5, 2015August 6, 2015

Pirfenidone (Esbriet) Shown As Safe, Effective in Daily Clinical Practice Treatment of IPF

News, Pulmonary Fibrosis News

Results from a recent study published in the journal Advance Therapy, showed that pirfenidone (known by the brand name Esbriet from Roche) is effective and has a safety profile ... Read more

July 17, 2015July 17, 2015

MUSC and Bristol-Myers Squibb Partner for Fibrotic Disease Research

News, Pulmonary Fibrosis News

Bristol-Myers Squibb Company and the Medical University of South Carolina recently signed a translational research partnership that will focus on fibrotic diseases, such as scleroderma, renal fibrosis, and idiopathic ... Read more

July 16, 2015July 16, 2015

OFEV (nintedanib) Added To Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)

News, Pulmonary Fibrosis News

Revised international treatment guidelines for Idiopathic Pulmonary Fibrosis (IPF) suggest use of OFEV (nintedanib), a proprietary drug from Ingelheim, Germany, based Boehringer Ingelheim Corporation for the treatment of the ... Read more

June 22, 2015June 22, 2015

Autoantibodies Targeted in New Strategy to Treat IPF

News, Pulmonary Fibrosis News

Novel research investigating the relationship between autoantibodies and idiopathic pulmonary fibrosis (IPF) may allow new therapies to be developed based on current treatments for autoimmune diseases. The laboratory of Steve ... Read more

Pin It on Pinterest